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Systemic sclerosis (SSc) is a connective tissue disorder characterized by fibrosis and 
vascular changes in the skin and internal visceral organs, with an autoimmune 
background. The increase of the collagen deposition is characteristic with SSc and 
depends on various cytokines. Among them, transforming growth factor-β (TGF- β) is 
considered to play a central role in the pathogenesis of SSc1. 
TGF- β may be involved not only fibrosis but also in autoimmune response in 
SSc. Recently, a subset of interleukin (IL)-17-producing helper T cells (Th17 cells) 
distinct from Th1 or Th2 cells have been shown to play a crucial role in the induction of 
autoimmune tissue injury. IL-17 is a member of a newly identified cytokine family 
comprising IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25) and IL-17F. IL-17 acts as 
a potent inflammatory cytokine in vitro and in vivo, with pleiotropic activities. IL-17 
regulates tissue inflammation by inducing the expression of proinflammatory cytokines 
such as IL-6 and TNFα, chemokines such as KC, MCP-1 and MIP-2, and matrix 
metalloproteases, which mediate tissue infiltration and tissue destruction. In addition, 
IL-17 costimulates T cells and enhances the maturation of dendritic cells. Importantly, 
TGF−β and IL-6 induce development of the Th17 cell lineage 2, while TGF- β alone 
induces CD4+CD25+Fop3+ regulatory T (Treg) cells. Since both TGF- β and IL-6 have 
been considered as crucial cytokines in SSc 1, 3, IL-17 and the Th17 response may be 
profoundly involved in the pathogenesis of SSc. Indeed, Kurosawa et al. have assessed 
16 SSc patients, and have demonstrated that serum IL-17 levels are increased in SSc 
patients. They also reported that IL-17 was overproduced by T cells in early stage of 
SSc 4. However, IL-17 levels and their clinical correlations have not been investigated 
in a large SSc population. Therefore, in this study, we examined the correlation of 
clinical and laboratory features with serum IL-17 levels in SSc patients. 
 Serum samples from 59 consecutive SSc patients referred to our hospital (12 
men and 47 women; median age, 49 years) were assessed for IL-17 levels. All patients 
fulfilled the criteria proposed by American College of Rheumatology. They were 
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classified into 28 patients with diffuse cutaneous SSc (dcSSc) and 31 limited cutaneous 
SSc (lcSSc) patients. No patients had been treated with corticosteroid or other 
immunosuppressive therapies. In a retrospective longitudinal analysis, we examined 
serum samples from 25 SSc patients (5 men and 20 women) whose sera were serially 
obtained for more than two consecutive years. During the follow-up period 20 patients 
had corticosteroid therapy. Fifteen healty donors (3 men and 12 women; median age, 47 
years) were included as controls. Complete medical histories, physical examinations, 
and laboratory tests including high resolution computed tomography of the chest were 
conducted for all patients at the first visit and during follow-up. Organ system 
involvement was defined as described previously 5. The duration of the disease was 
calculated from the time of onset of the first clinical event (other than Raynaud’s 
phenomenon) that was a clear manifestation of SSc. Serum IL-17 levels were measured 
using an ELISA kit (R&D Systems, Minneapolis, MN), according to the manufacturer’s 
protocol. Each sample was tested in duplicate. The protocol was approved by Kanazawa 
University Hospital, and informed consent was obtained from all patients. Statistical 
analysis was performed using Mann-Whitney U test for comparison of values, and 
Fisher's exact probability test for comparison of frequencies. P values less than 0.05 
were considered statistically significant.  
Serum IL-17 levels were significantly higher in SSc patients compared with 
normal controls (4.96 pg/ml vs. 1.15 pg/ml; p<0.0001, Fig. 1a), while there was no 
significant difference between dcSSc and lcSSc. When values higher than the mean + 
2SD (2.44 pg/ml) of the control serum samples were considered to be elevated, serum 
IL-17 levels were elevated in 85% (50/59) of SSc patients. The correlation between 
IL-17 levels and disease duration was not also recognized, although patients with 
normal serum IL-17 levels showed significantly higher modified Rodnan total skin 
thickness score (TSS) compared with those with elevated IL-17 levels (20.2 vs. 10.8, 
p<0.05, Table 1). There were no significant differences in frequencies of visceral 
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involvement including the esophagus, kidney, heart, and lung. Additionally, 
anti-topoisomerase I antibodies were positive in patients with normal serum IL-17 at a 
significantly higher rate than those with elevated serum IL-17 (78% vs. 35%, p<0.05). 
These results confirm that serum IL-17 levels are elevated in most SSc 
patients, suggesting that IL-17 is involved in a common pathway of SSc development 
regardless of the disease subset. Our results that elevated IL-17 levels correlated with 
lower TSS may indicate that IL-17 transiently increases in the earlier phase of the 
disease, which may be consistent with the report by Kurosawa et al. Furthermore, in our 
longitudinal analysis using serial sera, the tendency that serum IL-17 levels attenuate 
during the follow-up period was observed (Fig. 1b). 
TGF-β is conventionally regarded as an anti-inflammatory cytokine, while it 
paradoxically plays a major role in SSc, which is considered as an autoimmune disease. 
TGF- β alone induces Treg cells that inhibit autoimmunity and protect against tissue 
injury 6 7, but induces Th17 cells in the presence of IL-6 in mice. However, TGF- β may 
be dispensable in Th17 induction in human, where IL-1β has been demonstrated to play 
a dominant role in driving Th17 differentiation 8. Nonetheless, the current study 
possibly proposes a hypothesis that the dysregulated production of TGF-β and IL-6 may 
lead to the imbalance of Th17 vs. Treg in SSc. Furthermore, IL-17 induces IL-6 and 
IL-8 production and enhances the surface expression of intracellular adhesion 
molecule-1 in human fibroblasts 9. Alternatively, since IL-17 induces the expression of 
matrix metalloproteases that facilitate collagen metabolism 10, augmented IL-17 
production in SSc may serve as a protective factor against fibrotic process. Collectively, 
in addition to the recent identification of Th17 involvement in multiple sclerosis, 
rheumatoid arthritis, and inflammatory bowel diseases, Th17 cells may also be involved 
in the pathogenesis of SSc. 
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Sex, male:female 8:42 4:5 NS 
Disease duration (years) 5.2±7.1 4.6±6.8 NS 
Clinical features    
 Total skin thickness score 10.8±11 20.2±12 <0.05 
 Pitting scar 39% (19/49) 44% (4/9) NS 
 Nailfold bleeding 74% (37/50) 78% (7/9) NS 
Organ involvement    
 Lung 42% (21/50) 78% (7/9) NS 
  %VC 103±21% 96±18% NS 
  %DLco 63±18% 60±15% NS 
 Pulmonary hypertension 8% (4/49) 22% (2/9) NS 
 Heart 16% (8/49) 0% (0/9) NS 
 Kidney 2% (1/48) 0% (0/9) NS 
 Arthritis 38% (19/50) 44% (4/9) NS 
 Esophagus 46% (23/50) 44% (4/9) NS 
 Muscle 6% (3/50) 0% (0/9) NS 
Laboratory data    
 Positive anti-topoisomerase I antibody 35% (17/49) 78% (7/9) <0.05 
 Positive anticentromere antibody 38% (19/49) 11% (1/9) NS 
 Positive anti-U1RNP antibody 4% (2/49) 22% (2/9) NS 
NS = not significant (P>0.05) 
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Figure Legends 
 
Figure 1. (A) Serum IL-17 levels in patients with SSc and normal controls. Serum 
samples were obtained from 59 SSc patients and 15 normal controls. Serum IL-17 
levels were measured by an enzyme immunoassay. The cut-off value for serum IL-17 
levels was arbitrarily determined as the mean + 2SD (2.44 pg/ml; indicated by a dotted 
line) level in normal controls.  
(B) Serial changes in serum IL-17 levels during the follow-up period in 25 SSc patients. 
The duration of the disease was calculated from the time of onset of the first clinical 
event (other than Raynaud’s phenomenon) that was a clear manifestation of SSc. 
Patients with serum IL-17 levels being higher than the mean + 2SD of normal controls 
(horizontal dotted line) at more than one point were shown by line plot. 
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